The role of complement in C3 glomerulopathy

被引:69
|
作者
Zipfel, Peter F. [1 ,2 ]
Skerka, Christine [1 ]
Chen, Qian [1 ]
Wiech, Thorsten [3 ]
Goodship, Tim [4 ]
Johnson, Sally [4 ]
Fremeaux-Bacchi, Veronique [5 ,6 ]
Nester, Clara [7 ]
Rodriguez de Cordoba, Santiago [8 ,9 ]
Noris, Marina [10 ]
Pickering, Matthew [11 ]
Smith, Richard [7 ]
机构
[1] Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany
[2] Univ Jena, D-07745 Jena, Germany
[3] Univ Hosp Hamburg Eppendorf, Inst Pathol, Hamburg, Germany
[4] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[5] Hosp European Georges Pompidou, Assistance Publ Hop Paris, Paris, France
[6] Cordelier Res Ctr, Complement & Dis Team, INSERM, UMRS 1138, Paris, France
[7] Univ Iowa, Carver Coll Med, Otolaryngol, Iowa City, IA 52242 USA
[8] Ctr Invest Biol, Dept Med Celular & Mol, Madrid 28040, Spain
[9] Ctr Invest Biol, Ciber Enfermedades Raras, Madrid 28040, Spain
[10] Mario Negri Inst Pharmacol Res, Bergamo, Italy
[11] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England
关键词
Complement C3 glomerulopathy; MPGN membranoproliferative; Dense deposit diseases; C3 nephritic factor; DENSE DEPOSIT DISEASE; HEMOLYTIC-UREMIC SYNDROME; FACTOR-H-AUTOANTIBODIES; GLOMERULONEPHRITIS TYPE-II; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; ALTERNATIVE PATHWAY; NEPHRITIC FACTOR; MACULAR DEGENERATION; NEISSERIA-GONORRHOEAE; BINDING-AFFINITY;
D O I
10.1016/j.molimm.2015.03.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
C3 glomerulopathy describes a spectrum of disorders with glomerular pathology associated with C3 cleavage product deposition and with defective complement action and regulation (Fakhouri et al., 2010; Sethi et al., 2012b). Kidney biopsies from these patients show glomerular accumulation or deposition of C3 cleavage fragments, but no or minor deposition of immunoglobulins (Appel et al., 2005; D'Agati and Bomback, 2012; Servais et al., 2007; Sethi and Fervenza, 2011). At present the current situation asks for a better definition of the underlining disease mechanisms, for precise biomarkers, and for a treatment for this disease. The complement system is a self activating and propelling enzymatic cascade type system in which inactive, soluble plasma components are activated spontaneously and lead into an amplification loop (Zipfel and Skerka, 2009). Activation of the alternative pathway is spontaneous, occurs by default, and cascade progression leads to amplification by complement activators. The system however is self-controlled by multiple regulators and inhibitors, like Factor H that control cascade progression in fluid phase and on surfaces. The activated complement system generates a series of potent effector components and activation products, which damage foreign-, as well as modified self cells, recruit innate immune cells to the site of action, coordinate inflammation and the response of the adaptive immune system in form of B cells and T lymphocytes (Kohl, 2006; Medzhitov and Janeway, 2002; Ogden and Elkon, 2006; Carroll, 2004; Kemper and Atkinson, 2007; Morgan, 1999; Muller-Eberhard, 1986; Ricklin et al., 2010). Complement controls homeostasis and multiple reactions in the vertebrate organism including defense against microbial infections (Diaz-Guillen et al., 1999; Mastellos and Lambris, 2002; Nordahl et al., 2004; Ricklin et al., 2010). In consequence defective control of the spontaneous self amplifying cascade or regulation is associated with numerous human disorders (Ricklin and Lambris, 2007; Skerka and Zipfel, 2008; Zipfel et al., 2006). Understanding the exact action and regulation of this sophisticated homeotic cascade system is relevant to understand disease pathology of various complement associated human disorders. Furthermore this knowledge is relevant for a better diagnosis and appropriate therapy. At present diagnosis of C3 glomerulopathy is primarily based on the kidney biopsy, and histological, immmunohistological and electron microscopical evaluation (D'Agati and Bomback, 2012; Fakhouri et al., 2010; Medjeral-Thomas et al., 2014a,b; Sethi et al., 2012b). The challenge is to define the actual cause of the diverse glomerular changes or damages, to define how C3 deposition results in the reported glomerular changes, the location of the cell damage and the formation of deposits. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:21 / 30
页数:10
相关论文
共 50 条
  • [41] URINARY COMPLEMENT ACTIVATION PRODUCTS: ESTABLISHMENT AND UTILITY AS BIOMARKERS IN C3 GLOMERULOPATHY
    Podos, Steven
    Patel, Dharaben
    Zhao, Yongsen
    Thanassi, Jane
    Uknis, Marc
    Barbour, Tom
    Zelenkofske, Steven
    Huang, Mingjun
    [J]. MOLECULAR IMMUNOLOGY, 2019, 114 : 428 - 428
  • [42] Screening of genes encoding complement (regulatory) proteins in patients with C3 glomerulopathy
    Westra, D.
    van den Heuvel, L. P.
    van Wijk, J. A. E.
    Wetzels, J. F. M.
    van de Kar, N. C. A.
    [J]. MOLECULAR IMMUNOLOGY, 2013, 56 (03) : 249 - 249
  • [43] C3 glomerulopathy — understanding a rare complement-driven renal disease
    Richard J. H. Smith
    Gerald B. Appel
    Anna M. Blom
    H. Terence Cook
    Vivette D D’Agati
    Fadi Fakhouri
    Véronique Fremeaux-Bacchi
    Mihály Józsi
    David Kavanagh
    John D. Lambris
    Marina Noris
    Matthew C. Pickering
    Giuseppe Remuzzi
    Santiago Rodriguez de Córdoba
    Sanjeev Sethi
    Johan Van der Vlag
    Peter F. Zipfel
    Carla M. Nester
    [J]. Nature Reviews Nephrology, 2019, 15 : 129 - 143
  • [44] Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy
    Meuleman, Marie-Sophie
    Petitprez, Florent
    Pickering, Matthew C.
    Le Quintrec, Moglie
    Artero, Mikel Rezola
    Duval, Anna
    Rabant, Marion
    Gilmore, Alyssa
    Boyer, Olivia
    Hogan, Julien
    Servais, Aude
    Provot, Francois
    Gnemmi, Vivianne
    Eloudzeri, Maeva
    Grunenwald, Anne
    Buob, David
    Boffa, Jean-Jacques
    Moktefi, Anissa
    Audard, Vincent
    Goujon, Jean-Michel
    Bridoux, Frank
    Thervet, Eric
    Karras, Alexandre
    Roumenina, Lubka T.
    Bacchi, Veronique Fremeaux
    Van Huyen, Jean-Paul Duong
    Chauvet, Sophie
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (08): : 1034 - 1044
  • [45] Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
    Marina Noris
    Roberta Donadelli
    Giuseppe Remuzzi
    [J]. Pediatric Nephrology, 2019, 34 : 1311 - 1323
  • [46] Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
    Noris, Marina
    Donadelli, Roberta
    Remuzzi, Giuseppe
    [J]. PEDIATRIC NEPHROLOGY, 2019, 34 (08) : 1311 - 1323
  • [47] Screening of genes encoding complement (regulatory) proteins in patients with C3 glomerulopathy
    Westra, D.
    van den Heuvel, L. P.
    van Wijk, J. A. E.
    Wetzels, J. F. M.
    van de Kar, N. C. A. J.
    [J]. PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1559 - 1560
  • [48] Insights into the role of FHR5 in C3 glomerulopathy
    Ruseva, Marieta M.
    Malik, Talat H.
    Pickering, Matthew C.
    [J]. IMMUNOBIOLOGY, 2016, 221 (10) : 1167 - 1167
  • [49] A novel role for neutrophils and NETs in the pathogenesis of C3 glomerulopathy
    Maqsood, Maria
    Suntharalingham, Samuel
    Fine, Noah
    Cook, Terence
    Walker, Patrick
    Glogauer, Michael
    Palaniyar, Nades
    Licht, Christoph
    [J]. MOLECULAR IMMUNOLOGY, 2022, 141 : 119 - 120
  • [50] The role of a step wise complement-mediated neutrophil activation via NETosis in the pathogenesis of C3 glomerulopathy
    Maqsood, Maria
    Suntharalingham, Samuel
    Fine, Noah
    Walker, Patrick
    Ortiz-Sandoval, Carolina
    Khan, Meraj
    Glogauer, Michael
    Palaniyar, Nades
    Licht, Christoph
    [J]. PEDIATRIC NEPHROLOGY, 2023, 38 (07) : 2403 - 2404